1,451
Views
0
CrossRef citations to date
0
Altmetric
Articles

Characterization and initial demonstration of in vivo efficacy of a novel heat-activated metalloenediyne anti-cancer agent

, , , , , , , , , & show all
Pages 405-413 | Received 13 Jul 2021, Accepted 22 Dec 2021, Published online: 02 Mar 2022

References

  • Van Lanen SG, Shen B. Biosynthesis of enediyne antitumor antibiotics. Curr Top Med Chem. 2008;8(6):448–459.
  • Oei AL, Vriend LE, Crezee J, et al. Effects of hyperthermia on DNA repair pathways: one treatment to inhibit them all. Radiat Oncol. 2015;10:165.
  • Bull JM. An update on the anticancer effects of a combination of chemotherapy and hyperthermia. Cancer Res. 1984;44(10 Suppl):4853s–4856s.
  • Kong G, Braun RD, Dewhirst MW. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res. 2001;61(7):3027–3032.
  • Issels RD. Hyperthermia adds to chemotherapy. Eur J Cancer. 2008;44(17):2546–2554.
  • Li L, ten Hagen TL, Bolkestein M, et al. Improved intratumoral nanoparticle extravasation and penetration by mild hyperthermia. J Control Release. 2013;167(2):130–137.
  • Perez CA, Gillespie B, Pajak T, et al. Quality assurance problems in clinical hyperthermia and their impact on therapeutic outcome: a Report by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1989;16(3):551–558.
  • Bruggmoser G, Bauchowitz S, Canters R, et al. Quality assurance for clinical studies in regional deep hyperthermia. Strahlenther Onkol. 2011;187(10):605–610.
  • Myerson RJ, Moros EG, Diederich CJ, et al. Components of a hyperthermia clinic: recommendations for staffing, equipment, and treatment monitoring. Int J Hyperthermia. 2014;30(1):1–5.
  • Trefná HD, Crezee H, Schmidt M, et al. Quality assurance guidelines for superficial hyperthermia clinical trials: I. Clinical requirements. Int J Hyperthermia. 2017;33(4):471–482.
  • Trefná HD, Schmidt M, van Rhoon GC, et al. Quality assurance guidelines for interstitial hyperthermia. Int J Hyperthermia. 2019;36(1):277–294.
  • Datta NR, Schneider R, Puric E, et al. Proton irradiation with hyperthermia in unresectable soft tissue sarcoma. Int J Part Ther. 2016;3(2):327–336.
  • Tran S, Puric E, Walser M, et al. Early results and volumetric analysis after spot-scanning proton therapy with concomitant hyperthermia in large inoperable sacral chordomas. Br J Radiol. 2020;93(1107):20180883.
  • Datta NR, Puric E, Klingbiel D, et al. Hyperthermia and radiation therapy in locoregional recurrent breast cancers: a systematic review and Meta-analysis. Int J Radiat Oncol Biol Phys. 2016;94(5):1073–1087.
  • Datta NR, Rogers S, Ordóñez SG, et al. Hyperthermia and radiotherapy in the management of head and neck cancers: a systematic review and Meta-analysis. Int J Hyperthermia. 2016;32(1):31–40.
  • Hurwitz MD. Hyperthermia and immunotherapy: clinical opportunities. Int J Hyperthermia. 2019;36(sup1):4–9.
  • Cihoric N, Tsikkinis A, van Rhoon G, et al. Hyperthermia-related clinical trials on cancer treatment within the ClinicalTrials.gov registry. Int J Hyperthermia. 2015;31(6):609–614.
  • Tombesi P, D, Vece F, Bianchi L, et al. Thermal ablation of liver tumours: how the scenario has changed in the last decade. EMJ Hepatol. 2018;6:88–94.
  • Kok HP, Cressman ENK, Ceelen W, et al. Heating technology for malignant tumors: a review. Int J Hyperthermia. 2020;37(1):711–741.
  • Hamann PR, Hinman LM, Beyer CF, et al. An anti-CD33 antibody − calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjugate Chem. 2002;13(1):40–46.
  • Porter MR, Walker JM, Zaleski JM. The outliers: metal-mediated radical reagents for biological substrate degradation. Acc Chem Res. 2019;52(7):1957–1967.
  • Warner BP, Millar SP, Broene RD, et al. Controlled acceleration and inhibition of Bergman cyclization by metal chlorides. Science. 1995;269(5225):814–816.
  • Konig B, Hollnagel H, Ahrens B, et al. Activation of macrocyclic biaryl-enediynes by metal-Ion coordination. Angew Chem Int Ed Engl. 1995;34(22):2538–2540.
  • Benites PJ, Rawat DS, Zaleski JM. Metalloenediynes: Ligand field control of thermal bergman cyclization reactions. J Am Chem Soc. 2000;122(30):7208–7217.
  • Hamann PR, Hinman LM, Hollander I, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia . Bioconjug Chem. 2002;13(1):47–58.
  • Lindahl SE, Park H, Pink M, et al. Utilizing redox-mediated Bergman cyclization toward the development of dual-action metalloenediyne therapeutics. J Am Chem Soc. 2013;135(10):3826–3833.
  • Li B, Zhang M, Lu H, et al. Coordination‐accelerated radical formation from acyclic enediynes for tumor cell suppression. Chem Asian J. 2019;14(23):4352–4357.
  • Rawat DS, Zaleski JM. Mg2+-induced thermal enediyne cyclization at ambient temperature. J Am Chem Soc. 2001;123(39):9675–9676.
  • Porter MR, Lindahl SE, Lietzke A, et al. Metal-mediated diradical tuning for DNA replication arrest via template strand scission. Proc Natl Acad Sci U S A. 2017;114(36):E7405–E7414.
  • Routt SM, Zhu J, Zaleski JM, et al. Potentiation of metalloenediyne cytotoxicity by hyperthermia. Int J Hyperthermia. 2011;27(5):435–444.
  • Keller EJ, Porter M, Garrett JE, et al. Characterization of thermally activated metalloenediyne cytotoxicity in human melanoma cells. Radiat Res. 2018;190(2):107–116.
  • Garrett JE, Metzger M, Schmitt K, et al. Enhancement of cytotoxicity of enediyne compounds by hyperthermia: effects of various metal complexes on tumor cells. Radiat Res. 2020;193(2):107–118.
  • Yan P, Lyu X, Wang S, et al. Insufficient ablation promotes the metastasis of residual non-small cell lung cancer (NSCLC) cells via upregulating carboxypeptidase A4. Int J Hyperthermia. 2021;38(1):1037–1051.
  • Le Poole IC, van den Berg FM, van den Wijngaard RM, et al. Generation of a human melanocyte cell line by introduction of HPV16 E6 and E7 genes. In Vitro Cell Dev Biol Anim. 1997;33(1):42–49.
  • Gavande NS, VanderVere-Carozza P, Mishra AK, et al. Design and structure-guided development of novel inhibitors of the Xeroderma Pigmentosum Group A (XPA) protein-DNA interaction. J Med Chem. 2017;60(19):8055–8070.
  • Mishra AK, Dormi SS, Turchi AM, et al. Chemical inhibitor targeting the replication protein A-DNA interaction increases the efficacy of Pt-based chemotherapy in lung and ovarian cancer. Biochem Pharmacol. 2015;93(1):25–33.
  • Giaccia AJ, Hall EJ. Radiobiology for the radiologist. 7th ed. Amsterdam: Lippincott Williams & Wilkins; 2012.
  • Bergman RG. Reactive 1,4-dehydroaromatics. Acc Chem Res. 1973;6(1):25–31.
  • Jones RR, Bergman RG. p-Benzyne. Generation as an intermediate in a thermal isomerization reaction and trapping evidence for the 1,4-benzenediyl structure. J Am Chem Soc. 1972;94(2):660–661.
  • Povirk LF. DNA damage and mutagenesis by radiomimetic DNA-cleaving agents: Bleomycin, neocarzinostatin and other enediynes. Mutat Res. 1996;355(1-2):71–89.
  • Ward J. DNA damage produced by ionizing radiation in mammalian cells: Identities, mechanisms of formation, and reparability. Prog Nucleic Acid Res Mol Biol. 1988;35:95–125.
  • Dewey WC, Sapareto SA, Betten DA. Hyperthermic radiosensitization of synchronous Chinese hamster cells: relationship between lethality and chromosomal aberrations. Radiat Res. 1978;76(1):48–59.
  • Kelleher DK, Vaupel P. Vascular effects of localized hyperthermia. In: Baronzio GF, Hager ED, editors. Hyperthermia in cancer treatment: a primer. Georgetown (TX): Landes Bioscience; 2006. p. 94–104.
  • Ivanova K, Lambers B, van den Wijngaard R, et al. Immortalization of human melanocytes does not alter the de novo properties of nitric oxide to induce cell detachment from extracellular matrix components via cGMP. In Vitro Cell Dev Biol Anim. 2008;44(8–9):385–395.
  • Bowen AR, Hanks AN, Allen SM, et al. Apoptosis regulators and responses in human melanocytic and keratinocytic cells. J Invest Dermatol. 2003;120(1):48–55.
  • Colombo R, Salonia A, Leib Z, et al. Long‐term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin‐C alone as adjuvant treatment for non‐muscle‐invasive bladder cancer (NMIBC). BJU Int. 2011;107(6):912–918.
  • Issels RD, Lindner LH, Verweij J, et al. Effect of neoadjuvant chemotherapy plus regional hyperthermia on long-term outcomes among patients with localized high-risk soft tissue sarcoma: the EORTC 62961-ESHO 95 Randomized Clinical Trial. JAMA Oncol. 2018;4(4):483–492.
  • van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–240.
  • Dewey WC. Failla memorial lecture. The search for critical cellular targets damaged by heat. Radiat Res. 1989;120(2):191–204.
  • Grieco CA, Simon CJ, Mayo-Smith WW, et al. Percutaneous image-guided thermal ablation and radiation therapy: outcomes of combined treatment for 41 patients with inoperable stage I/II non-small-cell lung cancer. J Vasc Interv Radiol. 2006;17(7):1117–1124.
  • Dupuy DE. Image-guided thermal ablation of lung malignancies. Radiology. 2011;260(3):633–655.
  • Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer. 2014;14(3):199–208.
  • Al-Bataineh O, Jenne J, Huber P. Clinical and future applications of high intensity focused ultrasound in cancer. Cancer Treat Rev. 2012;38(5):346–353.